Evidence map›Paper›PMID 34865316›Full record

Observational studyBJOG : an international journal of obstetrics and gynaecology2022

Quality of life from cytoreductive surgery in advanced ovarian cancer: Investigating the association between disease burden and surgical complexity in the international, prospective, SOCQER-2 cohort study.

Sudha Sundar, Carole Cummins, Satyam Kumar, Joanna Long, Vivek Arora, Janos Balega, Tim Broadhead, Tim Duncan, Richard Edmondson, Christina Fotopoulou and 10 more

Open access · hybridAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in BJOG : an international journal of obstetrics and gynaecology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 3 pooled it
4.2field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 3 syntheses or guidelines pooled it, 26 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Observational
  16. NovelFrontiers in oncology · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 16 institutions in 3 countries.

Sudha SundarInstitute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK.ORCID 0000-0002-5843-3015
Carole CumminsInstitute of Applied Health Research, University of Birmingham, Birmingham, UK.
Satyam KumarInstitute of Applied Health Research, University of Birmingham, Birmingham, UK.ORCID 0000-0001-9832-7324
Joanna LongInstitute of Applied Health Research, University of Birmingham, Birmingham, UK.
Vivek AroraBondi Women's Health, Sydney, NSW, Australia.
Janos BalegaSandwell and West Birmingham NHS Trust, Birmingham, UK.
Tim BroadheadLeeds Teaching Hospitals NHS Trust, Leeds, UK.
Tim DuncanNorfolk & Norwich University Hospital, Norwich, UK.
Richard EdmondsonUniversity of Manchester, Manchester, UK.ORCID 0000-0003-2553-4423
Christina FotopoulouImperial College London, London, UK.
Ros GlasspoolUniversity of Glasgow, Glasgow, UK.
Desiree KolomainenKings College NHS Foundation Trust, London, UK.
Simon LeesonBetsi Cadwaladr University Health Board, Bangor, UK.
Ranjit ManchandaWolfson Institute of Population Health, Queen Mary University of London, London, UK.ORCID 0000-0003-3381-5057
Orla McNallyPeter MacCallum Cancer Centre, Melbourne, Vic., Australia.
Jo MorrisonTaunton and Somerset NHS Foundation Trust, Taunton, UK.ORCID 0000-0003-0000-520X
Asima MukhopadhyayTata Medical Center, Kolkata, India.
Jim PaulUniversity of Glasgow, Glasgow, UK.
John TidyUniversity of Sheffield, Sheffield, UK.ORCID 0000-0002-0872-7971
Nick WoodLancashire Teaching Hospitals NHS Foundation Trust, Preston, UK.
University of Birmingham · GBSandwell & West Birmingham Hospitals NHS Trust · GBUniversity of Glasgow · GBBetsi Cadwaladr University Health Board · GBBond University · AUImperial College London · GBKing's College Hospital NHS Foundation Trust · GBLancashire Teaching Hospitals NHS Foundation Trust · GBLeeds Teaching Hospitals NHS Trust · GBNorfolk and Norwich University Hospital · GBPeter MacCallum Cancer Centre · AUQueen Mary University of London · GBTata Medical Center · INTaunton & Somerset NHS Foundation Trust · GBUniversity of Manchester · GBUniversity of Sheffield · GB

Funding

Australian Society of Gynaecologic Oncologists IncDepartment of Science Technology, India - UKIERIJiv Daya FoundationNational Institute of Health and Care Excellence
6 · The paper itself

Abstract

objectiveTo investigate quality of life (QoL) and association with surgical complexity and disease burden after surgical resection for advanced ovarian cancer in centres with variation in surgical approach.

designProspective multicentre observational study.

settingGynaecological cancer surgery centres in the UK, Kolkata, India, and Melbourne, Australia. SAMPLE: Patients undergoing surgical resection (with low, intermediate or high surgical complexity score, SCS) for late-stage ovarian cancer.

main outcome measuresPrimary: change in global score on the European Organisation for Research and Treatment of Cancer (EORTC) core quality-of-life questionnaire (QLQ-C30). Secondary: EORTC ovarian cancer module (OV28), progression-free survival.

resultsPatients' preoperative disease burden and SCS varied between centres, confirming differences in surgical ethos. QoL response rates were 90% up to 18 months. Mean change from the pre-surgical baseline in the EORTC QLQ-C30 was 3.4 (SD 1.8, n = 88) in the low, 4.0 (SD 2.1, n = 55) in the intermediate and 4.3 (SD 2.1, n = 52) in the high-SCS group after 6 weeks (p = 0.048), and 4.3 (SD 2.1, n = 51), 5.1 (SD 2.2, n = 41) and 5.1 (SD 2.2, n = 35), respectively, after 12 months (p = 0.133). In a repeated-measures model, there were no clinically or statistically meaningful differences in EORTC QLQ-C30 global scores between the three SCS groups (p = 0.840), but there was a small statistically significant improvement in all groups over time (p < 0.001). The high-SCS group experienced small to moderate decreases in physical (p = 0.004), role (p = 0.016) and emotional (p = 0.001) function at 6 weeks post-surgery, which resolved by 6-12 months.

conclusionsThe global QoL of patients undergoing low-, intermediate- and high-SCS surgery improved at 12 months after surgery and was no worse in patients undergoing extensive surgery. TWEETABLE ABSTRACT: Compared with surgery of lower complexity, extensive surgery does not result in poorer quality of life in patients with advanced ovarian cancer.

Indexed as

Ovarian NeoplasmsQuality of LifeCarcinoma, Ovarian EpithelialCohort StudiesCost of IllnessCytoreduction Surgical ProceduresFemaleHumansProspective StudiesSurveys and Questionnairesextensive surgeryovarian cancerquality of lifeultraradical surgery

Identifiers

PMID34865316
PMCPMC9306902
OpenAlexW4200448460

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.